Home Wealth Advisor Sarepta Therapeutics Inc (SRPT) Shares Sold by Vanguard Capital Wealth Advisors – Fairfield Current

Sarepta Therapeutics Inc (SRPT) Shares Sold by Vanguard Capital Wealth Advisors – Fairfield Current

7 min read
0
110


Vanguard Capital Wealth Advisors reduced its position in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 4.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,700 shares of the biotechnology company’s stock after selling 200 shares during the period. Vanguard Capital Wealth Advisors’ holdings in Sarepta Therapeutics were worth $512,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Cornerstone Advisors Inc. bought a new stake in Sarepta Therapeutics in the 3rd quarter worth approximately $25,000. First Quadrant L P CA bought a new stake in shares of Sarepta Therapeutics during the 3rd quarter valued at $130,000. Ffcm LLC bought a new stake in shares of Sarepta Therapeutics during the 3rd quarter valued at $162,000. Advisory Research Inc. bought a new stake in shares of Sarepta Therapeutics during the 3rd quarter valued at $214,000. Finally, GWM Advisors LLC bought a new stake in shares of Sarepta Therapeutics during the 3rd quarter valued at $221,000. Institutional investors own 90.93% of the company’s stock.

Shares of SRPT stock opened at $139.71 on Friday. The firm has a market capitalization of $9.34 billion, a price-to-earnings ratio of -85.19 and a beta of 1.91. Sarepta Therapeutics Inc has a 52 week low of $50.68 and a 52 week high of $176.50. The company has a debt-to-equity ratio of 0.65, a quick ratio of 7.84 and a current ratio of 8.85.

SRPT has been the subject of a number of recent research reports. BidaskClub raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, October 18th. Royal Bank of Canada reissued an “outperform” rating and set a $164.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, January 17th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $217.00 target price on shares of Sarepta Therapeutics in a report on Monday, November 26th. Zacks Investment Research raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating and set a $147.00 target price for the company in a report on Tuesday, October 16th. Finally, Credit Suisse Group upped their target price on shares of Sarepta Therapeutics from $178.00 to $189.00 in a report on Thursday, October 4th. Four research analysts have rated the stock with a hold rating, twenty-three have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $182.32.

COPYRIGHT VIOLATION WARNING: “Sarepta Therapeutics Inc (SRPT) Shares Sold by Vanguard Capital Wealth Advisors” was originally reported by Fairfield Current and is the property of of Fairfield Current. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.fairfieldcurrent.com/news/2019/02/01/vanguard-capital-wealth-advisors-lowers-stake-in-sarepta-therapeutics-inc-srpt.html.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Further Reading: What Does Beta Mean In Stock Selection

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sarepta Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Let’s block ads! (Why?)


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also

Patagonia Will Not Comment on the Finance Bro Vest Controversy – Outside

If you followed the story that sent shivers through the finance and tech worlds, then you …